Skip to main content
Michelle Fanale, MD, Oncology, Bothell, WA

Michelle A. Fanale MD

Hematologic Oncology


Executive Medical Director, Lymphoma Strategy

Join to View Full Profile
  • Seagen - Headquarters21717 30th Drive S.E, Building 3Bothell, WA 98021

  • Phone+1 425-527-4000

Dr. Fanale is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 1999
  • Rutgers College
    Rutgers College BA, Biochemistry/ Molecular Biology & Psychology , 1990 - 1994

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2002 - 2022
  • AZ State Medical License
    AZ State Medical License 2001 - 2017
  • MN State Medical License
    MN State Medical License 2000 - 2015

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma  
    Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
  • Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study  
    Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica

Lectures

  • Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • My B-cell Lymphoma Treatment During Pregnancy
    My B-cell Lymphoma Treatment During PregnancyJune 21st, 2018
  • Novel Agents Show Impressive Activity in Hodgkin Lymphoma
    Novel Agents Show Impressive Activity in Hodgkin LymphomaOctober 27th, 2017
  • Longer Nivolumab Response Reported in Hodgkin Lymphoma Patients
    Longer Nivolumab Response Reported in Hodgkin Lymphoma PatientsAugust 10th, 2017
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: